

(19) World Intellectual Property  
Organization  
International Bureau



549662

(43) International Publication Date  
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number  
**WO 2004/082463 A2**

(51) International Patent Classification<sup>7</sup>:

**A61B**

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2004/008129

(22) International Filing Date: 16 March 2004 (16.03.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/455,705

17 March 2003 (17.03.2003) US

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): MEDICAL COLLEGE OF OHIO [US/US]; 3035 Arlington Avenue, Toledo, OH 43614-5804 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): RATNAM, Manohar [US/US]; 2266 St. Roberts Lane, Toledo, OH 43617 (US).


Published:

— without international search report and to be republished upon receipt of that report

(74) Agents: MARTINEAU, Catherine, B. et al.; Emch, Schaffer, Schaub & Porcello Co. L.P.A., P.O. Box 916, Toledo, OH 43697-0916 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FOLATE RECEPTOR GENE MODULATION FOR CANCER DIAGNOSIS AND THERAPY



(57) Abstract: A method of diagnosing and treating a patient with or suspected of having at least one solid tumor that produces folate receptor type  $\alpha$  includes administering a biologically effective amount of at least one folate receptor  $\alpha$  inducer, specifically steroid receptor ligands, with or without aid from at least one histone deacetylase inhibitor, to increase the level of the folate receptor  $\alpha$  on the plasma membrane of cancer cells as well as the folate receptor  $\alpha$  in at least one type of body fluid, including, for example, serum, ascites and cerebrospinal fluid.

WO 2004/082463 A2